Introduction: Cisplatin/etoposide regimen is the recommended first line treatment for poorly differentiated grade 3 neuroendocrine carcinoma (G3-NEC). There is no standard second line.
Aim(s): We analyzed the antitumor efficacy of oxaliplatin-based chemotherapy (Ox-bC) in G3-NEC patients (pts).
Materials and methods: This is a single center retrospective analysis of consecutive G3-NEC pts treated with Ox-bC between December 2003 and June 2012. Primary endpoint was progression-free survival (PFS) and secondary endpoints were overall survival (OS), response rate (RR) and safety.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Julien Hadoux
, Guigay J
, Malka D
, Planchard D
, Boige V
, Burtin P
, Loriot Y
, Duvillard P
, Scoazec J Y
, Schlumberger M
, Ducreux M
, Baudin E
To read results and conclusion, please login ...
Further abstracts you may be interested in